Claims for Patent: 11,160,888

Summary for Patent: 11,160,888

Title:	PET tracer for imaging of neuroendocrine tumors
Abstract:	There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Inventor(s):	Kjaer; Andreas (Frederiksberg, DK), Knigge; Ulrich (Kobenhavn O, DK), Hojgaard; Liselotte (Kobenhavn O, DK), Rasmussen; Palle (Roskilde, DK)
Assignee:	SOMSCAN APS (Frederiksberg, DK)
Application Number:	16/454,631
Patent Claims:	1. A method for imaging a somatostatin receptor-expressing tumor in a human patient, the method comprising: a) administering to the human patient an imaging composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof: ##STR00003## b) conducting a radiographic imaging method on the patient, within 24 hours after administration of the imaging composition; and c) making a radiographic image of the patient for detecting the compound of Formula I; wherein the imaging composition is administered with a target dose in the range of 150-350 MBq and wherein the radiographic image is diagnostic for the presence of a somatostatin receptor-expressing tumor in the patient. 2. The method of claim 1, wherein the imaging composition further comprises a scavenger. 3. The method of claim 2, wherein the scavenger is gentisic acid. 4. The method of claim 1, wherein the imaging composition further comprises sodium acetate. 5. The method of claim 1, wherein the somatostatin receptor being expressed is a somatostatin receptor selected from the group consisting of SST1-SST2. 6. The method of claim 1, wherein the somatostatin receptor being expressed is SST2. 7. The method of claim 1, wherein the somatostatin receptor-expressing tumor is a somatostatin receptor-expressing tumor metastasis. 8. The method of claim 1, wherein the tumor is a neuroendocrine tumor. 9. The method of claim 1, wherein the tumor is a neuroendocrine tumor metastasis. 10. The method of claim 1, wherein the radiographic imaging method is performed at a time after administration of the imaging composition, the time selected from the group consisting of 1hour, 3 hours. 11. The method of claim 1, wherein the radiographic imaging method is selected from the group consisting of planar imaging, positron emission tomography (PET), computed tomography (CT), single photon computed tomography (SPECT), and combinations thereof. 12. The method of claim 1, wherein the compound of Formula I or a pharmaceutically acceptable salt thereof is administered to predict effectiveness of a radionuclide therapy drug for treating a somatostatin receptor-expressing tumor in a human patient, the method further comprising detecting uptake by the tumor of the compound of Formula I or a pharmaceutically acceptable salt thereof. 13. The method of claim 12, wherein the radionuclide therapy drug comprises Lu-177 DOTATATE. 14. The method of claim 12, wherein the somatostatin receptor being expressed is SST2. 15. The method of claim 12, wherein the somatostatin receptor-expressing tumor is selected from the group consisting of a somatostatin receptor- expressing tumor metastasis, a neuroendocrine tumor and a neuroendocrine tumor metastasis. 16. The method of claim 1, wherein the human patient was a patient that had received a radionuclide therapy drug for therapeutic treatment of a somatostatin receptor-expressing tumor prior to the administration of the compound of Formula I or a pharmaceutically acceptable salt thereof. 17. The method of claim 16, wherein the compound of Formula I or a pharmaceutically acceptable salt thereof is administered to monitor the effect of the therapeutic treatment of the somatostatin receptor-expressing tumor in the patient by detecting uptake by cell receptors of the compound of Formula I or a pharmaceutically acceptable salt. 18. The method of claim 17, wherein the somatostatin receptor being expressed is SST2. 19. The method of claim 17, wherein the somatostatin receptor-expressing tumor is selected from the group consisting of a somatostatin receptor-expressing tumor metastasis, a neuroendocrine tumor and a neuroendocrine tumor metastasis. 20. The method of claim 17, wherein the radionuclide therapy drug comprises Lu-177 DOTATATE.